Prosensa to Appoint Michael Wyzga to Supervisory Board

Leiden, The Netherlands, April 8, 2014 (GLOBE NEWSWIRE) — Prosensa Holding N.V. (NASDAQ: RNA), the Dutch bio­phar­ma­ceu­ti­cal com­pa­ny focus­ing on rare dis­eases with a high unmet med­ical need, today announced that Michael S. Wyzga has been nom­i­nat­ed for appoint­ment to its Supervisory Board at the next share­hold­ers’ meet­ing, sched­uled for June 17, 2014.
“We wel­come Michael as an instru­men­tal addi­tion to our Supervisory Board,” said Hans Schikan, Prosensa’s CEO. “Michael’s exten­sive finan­cial and trans­ac­tion­al exper­tise will sup­port the com­pa­ny sig­nif­i­cant­ly in our efforts to bring much-need­ed, life-sav­ing treat­ments for rare genet­ic dis­eases to patients. His long-term tenure at Genzyme, one of the most suc­cess­ful com­pa­nies in the rare dis­ease space, will be invalu­able as we con­tin­ue devel­op­ing ther­a­pies for boys with Duchenne mus­cu­lar dys­tro­phy and build­ing our com­pa­ny.”
Mr. Wyzga most recent­ly served as President and Chief Executive Officer of Radius Health. Prior to join­ing Radius, Mr. Wyzga was Executive Vice President and Chief Financial Officer of Genzyme Corporation until its $20.1 bil­lion acqui­si­tion by Sanofi in April 2011. He joined Genzyme in 1998 and held pri­ma­ry respon­si­bil­i­ty for the company’s finan­cial man­age­ment world­wide. Mr. Wyzga cur­rent­ly serves on the board of direc­tors for OncoMed Pharmaceuticals, Akebia Therapeutics and Idenix Pharmaceuticals.
“Michael’s cor­po­rate lead­er­ship expe­ri­ence in rare dis­eases makes him an ide­al fit for Prosensa, and his con­tri­bu­tion will be vital as the com­pa­ny works to suc­cess­ful­ly advance its DMD drug pipeline,” said David Mott, Chairman of Prosensa’s Supervisory Board.
“I am pleased to join Prosensa at such a sig­nif­i­cant moment in the company’s his­to­ry and look for­ward to work­ing along­side a world-class team with excep­tion­al lead­er­ship in rare dis­eases,” said Michael Wyzga. “It is an hon­or to be able to share my expe­ri­ence and con­tribute to the future direc­tion and growth of a com­pa­ny work­ing so dili­gent­ly to find a ther­a­peu­tic option for boys with this dev­as­tat­ing dis­ease.”

Leave a Reply

Your email address will not be published. Required fields are marked *